Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 97

Results For "risk"

1375 News Found

CorePath partners with Cizzle Bio to develop blood test to detect lung cancer
Biotech | May 27, 2022

CorePath partners with Cizzle Bio to develop blood test to detect lung cancer

Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths


European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer
Drug Approval | May 25, 2022

European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer

This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC


Lonza partners with Israel Biotech Fund to support biologics and small molecules development
Biotech | May 25, 2022

Lonza partners with Israel Biotech Fund to support biologics and small molecules development

The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets


Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Drug Approval | May 24, 2022

Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol

Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.


Apollo Hospitals Navi Mumbai doctors perform critical procedure to save 14-month-old baby girl
Hospitals | May 24, 2022

Apollo Hospitals Navi Mumbai doctors perform critical procedure to save 14-month-old baby girl

Successfully removed peanut from the child’s left lung through bronchoscopy


CHMP recommends European Commission approval of Rinvoq
Drug Approval | May 23, 2022

CHMP recommends European Commission approval of Rinvoq

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients


50% of the world's population expected to be myopic by 2050
News | May 23, 2022

50% of the world's population expected to be myopic by 2050

Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear


Novartis Cosentyx receives positive CHMP opinion for use in childhood arthritic conditions
Biotech | May 21, 2022

Novartis Cosentyx receives positive CHMP opinion for use in childhood arthritic conditions

Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU


USFDA approves Dupixent as first treatment for 12 and older with eosinophilic esophagitis
Drug Approval | May 21, 2022

USFDA approves Dupixent as first treatment for 12 and older with eosinophilic esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date


Havas Health & You appoints Dan Rubin as President of Havas Health +
People | May 20, 2022

Havas Health & You appoints Dan Rubin as President of Havas Health +

Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum